Top ASX gainers today

Carnegie Clean Energy, Imugene and EOS are gaining attention after recent operational progress, funding updates, technology developments and expansion activities.

Carnegie Clean Energy Limited (ASX: CCE)

Carnegie Clean Energy Limited on 15 May 2026, announced that its subsidiary, CETO Wave Energy Ireland, received a EuropeWave payment of €63,688 (around AUD 103k) for the ACHIEVE Programme after securing deployment approvals at the BiMEP site in Spain and completing control software for PTO testing.
On 7 May 2026, the company confirmed selection for technical support under the US TEAMER program valued at about USD 194k (around AUD 270k). The project with Kelson Marine will study integration of MoorPower technology with offshore fish pens to reduce diesel use in aquaculture operations through advanced numerical modelling work.

For the quarter ended 31 March 2026, Carnegie stated that fabrication and testing activities under the ACHIEVE Programme continued ahead of deployment and operations planned later in the year. 
During the same quarter, the Blue Economy CRC funded MoorPower preliminary design project moved from validation work toward commercial pilot development with aquaculture stakeholders. Carnegie also engaged with defence sector partners to examine wave energy applications for defence use.

Imugene Limited (ASX: IMU)

Imugene Limited  on 22 May 2026, announced positive Phase 1b azer-cel data in CAR T-naive patients across several blood cancer types. Among 16 evaluable patients, the overall response rate was 81%, including strong results in MZL, CLL, FL and WM. Updated data will be presented at ASCO on 29 May 2026 in Chicago.

During the quarter ended 31 March 2026, the company achieved 100% overall response rates in CLL/SLL patients and 80% in MZL from the azer-cel study. The trial protocol was also expanded to include a BTKi combination arm and Mantle Cell Lymphoma.

Imugene received an R&D tax refund of A$2.74 million for FY2025 and completed a $16 million capital raising from institutional and retail investors during the quarter.

The Phase 1b azer-cel trial is running across 10 US and 5 Australian sites for patients with relapsed or refractory CD19+ blood cancers. The further patient data and enrolment updates are expected in coming months.

Electro Optic Systems Holdings Limited (ASX: EOS) 

Electro Optic Systems Holdings Limited  confirmed the completion of the MARSS acquisition on 21 May 2026. The MARSS NiDAR platform has recently been used to protect critical assets in the Middle East from drone attacks with systems and personnel active across the region.

EOS completed a fully underwritten institutional placement raising A$150M through the issue of about 18.8 million new shares at A$8.00 each on 20 May 2026. The new shares are expected to begin trading on 25 May 2026.

Also on 20 May 2026, EOS announced a further A$40 million strategic placement involving Calidus-related entity Generation 5 Holding and another defence-focused institutional investor, subject to shareholder approval at an expected June meeting.

(Source: Company Report)